Subcutaneous interferon beta-1a has a positive effect on cognitive performance in mildly disabled patients with relapsing—remitting multiple sclerosis: 2-year results from the COGIMUS study
The effect of interferon (IFN) beta-1a (44 and 22 μg subcutaneously [sc] three times weekly [tiw]) on cognition in mildly disabled patients with relapsing—remitting multiple sclerosis (McDonald criteria; Expanded Disability Status Scale ≤4.0) was assessed by validated neuropsychological testing at b...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2009-03-01
|
Series: | Therapeutic Advances in Neurological Disorders |
Online Access: | https://doi.org/10.1177/1756285608101379 |